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Received May 26, 2015; accepted October 13, 2015AbstractBackground: Gamma knife radiosurgery (GKRS) has become an effective salvage therapeutic option for recurrent ependymomas. However, its
effectiveness can be assessed only by neuroimaging before clinical deterioration occurs. We analyzed the evolution of post-GKRS magnetic
resonance imaging (MRI) features and sought to establish the feasibility of timely appropriate clinical management of the recurrent tumors.
Methods: We retrospectively investigated 19 recurrent ependymomas of 11 patients treated with GKRS in our hospital from 1994 to 2013. All
included tumors had sequential MRI at 3e6-month intervals, and tumor response was volumetrically calculated on consecutive MRI.
Results: Post-GKRS tumors might show an increased enhancement or loss of enhancement associated with tumor enlargement or straight
shrinkage. Seven of 19 tumors (37%) had continuously regressed or remained stable up to the last follow-up. Twelve of 19 tumors (63%) showed
enlargement of enhancing lesions through examination of the post-GKRS follow-up MRI within the first 18 months. Five of 12 tumors (42%)
showed continuous enlargement, which was interpreted as true progression; seven of 12 (58%) exhibited transient increasing enhanced volume
that resolved within 6 months, and which was interpreted as pseudoprogression. There was no significant association between the presence of
pseudoprogression and the pathological grades or locations of the tumors, and the concomitant chemotherapy or previous radiotherapy. Sta-
tistically significant differences were found for mean apparent diffusion coefficient (ADC) values and ADC ratio (prior to and after GKRS) of
enhancing lesions between pseudoprogression and true progression.
Conclusion: The MRI patterns of post-GKRS recurrent ependymomas are heterogeneous. Transient increased tumor volume may represent
pseudoprogression, whose final tumor control rate was not significantly different from those cases with straight tumor shrinkage. ADC values,
ADC ratio, and sequential follow-up MRI scans are beneficial to differentiate between pseudoprogression and true progression, and help guide
clinical management.
Copyright © 2015, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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Intracranial ependymomas are the third most common
primary brain tumors in children1 and constitute 4% of adult
tumors.2 Despite aggressive initial treatment, tumor recurrence
is common, and treatment options of a recurrent ependymoma
are often limited by previous therapies. Gamma knife radio-
surgery (GKRS) has become an effective salvage therapeuticsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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treatment can be assessed only by neuroimaging prior to onset
of clinical deteriorated. The purpose of this study was to
evaluate the evolution of tumor response to GKRS and
ascertain the feasibility of offering timely further appropriate
management of these tumors, if clinical status warranted.
2. Methods
All aspects of the work covered in this manuscript followed
the principles of World Medical Association Declaration of
Helsinki. A total of 11 patients (19 tumors) with relapsed
ependymoma treated by GKRS at our institute from 1994 to
2013 were included. All patients had undergone surgical
tumor resection at the time of diagnosis, followed by
sequential magnetic resonance imaging (MRI) at 3e6-month
intervals for at least 12 months, and had new recurrent le-
sions revealed by follow-up MR images. We retrospectively
reviewed the MR images and the clinical data, including pa-
tient age, tumor grade, tumor location, extent of surgical
resection, and the treatment regimen. All tumors were classi-
fied according to the World Health Organization classification
(2007).32.1. MRIMRI was performed using 1.5-T clinical MRI scanners
(GE Medical Systems, Milwaukee, WI, USA), with conven-
tional circularly polarized head coils and intravenous
administration of standard doses of gadolinium-based
contrast. All tumor volumes were defined by neuroradiolo-
gists as the sum of tumor segmentation on all tumor slices
based on Gd-enhanced spin-echo T1-weighted MRI (3-mm
slice thickness, no gap). For each lesion, the same imaging
protocol and volumetric measurement were applied at every
follow-up time point.
Of the lesions that showed increased enhancing area after
GKRS, absolute apparent diffusion coefficient (ADC) values
of the tumor or enhancing lesions prior to and after GKRS
were measured retrospectively by placing regions of interest
delineated according to the tumor geometry on ADC maps
with OsiriX MD imaging software version 7.0. We measured
the lesions with an increased size of the enhancing area after
GKRS, and obtained ADC ratios (ADC of the enlarged
enhancing lesion after GKRS to ADC of the treated tumor
prior to GKRS). Thereafter, the dynamic changes of post-
therapeutic imaging patterns and the long-term volume
changes were analyzed.
Tumor recurrence was radiologically defined as a new
enhancing lesion with steady growth of enhancement and/or
mass effect on follow-up MRIs. Pseudoprogression was
radiologically defined as transient enlargement of an
enhancing lesion followed by tumor regression on MRIs, and
true progression was defined as persistent enlargement of an
enhancing lesion on MRIs or pathologically verified through
surgical resection. Local tumor recurrence was defined as a
new enhancing lesion at the previous operative bed; infieldrecurrence after GKRS as a new enhancing lesion that
occurred 2 years later at prior GKRS treated area; and distant
recurrence as a new enhancing lesion at the site other than
local tumor recurrence.2.2. GKRSStereotactic radiosurgery was performed using the Gamma
Knife (Leksell; Elekta, Inc., Atlanta, GA, USA). Transaxial
and coronal contrast-enhanced T1- and T2-weighted imaging
were used for dose planning of GKRS in all cases. In 17 tu-
mors, the GKRS treatment volumes were defined according to
the enhancing tumor components. In the other two patients,
who had a nonenhancing tumor, the GKRS treatment volumes
were based on T2-weighted imaging volumes. Contrast-
enhanced T1-weighted imaging were acquired after bolus in-
jection of contrast medium (0.1 mmol/kg) with a 3-mm slice
thickness and no gap. The mean tumor volume was 3.02
(range 0.07e18.95) mL prior to GKRS. The tumor volume of
the only grade II ependymoma case was 0.77 mL, and the
mean tumor volume of grade III (anaplastic) ependymomas
was 3.15 mL. The median prescription dose delivered to the
margins of the tumor was 13 Gy (range, 12e24 Gy), at
55e68% isodose levels. A median of 10 isocenters (range,
4e21) per tumor was used for the GKRS.2.3. StatisticsWe used Fisher exact test and logistic regression for com-
parison of independent variables because some cells had low
expected frequencies (fewer than 5). Local tumor control were
estimated using KaplaneMeier curves and a univariable log-
rank test based on the dates of diagnosis, first GKRS ses-
sion, follow-up MRI, and last follow-up or death. All statis-
tical analyses were performed using SPSS (version 19.0;
SPSS, Chicago, IL, USA), using two-sided statistical testing at
the 5% significance level.
3. Results
The current analysis ultimately comprised 19 tumors of 11
patients, of whom six were male and five female, aged 2e45
(median 12) years. Histologic diagnosis of the primary site in
these cases was as follows: one (9%) World Health Organi-
zation (WHO) grade II ependymoma, and 10 (91%) WHO
grade III anaplastic ependymomas. Eight treated lesions were
supratentorially (including 5 local and/or infield recurrences
and 3 distant metastases) and 11 were infratentorially located
(10 local recurrences and 1 distant metastasis). Subsequent to
tumor resection, all but one patient underwent a full course of
fractionated RT. Among them, six patients received cranial
radiation only, and four patients also received neuraxis RT.
Five patients had pre-GKRS chemotherapy. The median in-
terval between RT and GKRS was 42 months (range,
4e131 months).
Seven of 19 tumors (37%) showed a post-GKRS straight
decrease in the tumor size. Twelve of 19 tumors (63%) showed
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MRI within the first 18 months. Seven of the tumors (58%)
were defined as pseudogression, and the other five (42%) were
true progression. The onset of pseudoprogression was
observed at 7.9 (4.8e10) months post-GKRS, and the onset of
true progression was observed at 4.9 (3e8) months post-
GKRS, respectively (Fig 1). The post-GKRS tumors showed
persistent enhancement, increased enhancement or partial loss
of enhancement, while the tumor volumes might be stable,
decreasing or increasing (Figs. 2 and 3). Additionally, the
enhancing patterns and tumor volumes might change over
time. In the current study, there was no lesion of true pro-
gression showing persistent enhancement and there was no
lesion exhibiting shrinkage or stability showing new
enhancement after GKRS. However, the enhancing pattern at
the time of tumor enlargement did not differ between tumors
with pseudoprogression and true progression ( p ¼ 0.92). The
age at GKRS, the pathological grades or locations of the
treated tumors, whether concomitant chemotherapy or temo-
zolomide was being used, the dose of previous RT, and the
time interval between RT and GKRS did not differ signifi-
cantly between pseudoprogression and true progression. The
mean prescribed dose of GKRS, tumor volume at GKRS, and
dose at tumor margins did not differ between pseudoprog-
ression and true progression. All pseudoprogression of tumor
except one decreased in size within a 6-month follow-up,
whereas all lesions of true progression persisted and were
enlarged on follow-up MRI scans ( p ¼ 0.03). One exceptional
pseudoprogression showed tumor shrinkage after 30 months
post-GKRS, and was the only WHO grade II ependymoma inFig. 1. Line plots of the volume change (in percentagthe current study. In that case, the tumor size peaked at
15 months post-GKRS, and slowly regressed to a small
enhancing nodule, which was smaller than the pre-GKRS
tumor and remained stable up to 89 months post-GKRS.
After excluding one case of pseudoprogression with post-
GKRS intratumoral hemorrhage, and two cases without pre-
GKRS diffusion-weighted images, absolute ADC values and
ADC ratios were obtained and nine of the 12 tumors showed
enlargement of enhancing lesions at the post-GKRS follow-up
MRI. ADC values were significantly higher in lesions of
pseudoprogression (1.41 ± 0.23  103 mm2/s;
mean ± standard deviation) than in true progression
(0.85 ± 0.06  103 mm2/s; p ¼ 0.002). ADC ratios were also
significantly higher in lesions of pseudoprogression
(1.15 ± 0.11; mean ± standard deviation) than in true pro-
gression (0.92 ± 0.02; p ¼ 0.005). The variables between the
pseudoprogression and true progression groups are summa-
rized in Table 1.
The mean local control time of GKRS was 28.9 (3e51)
months. KaplaneMeier curves generated for local tumor
control showed that tumors with pseudoprogression features
were associated with 1- and 2-year local control rates of 100%
and 67%, respectively. Patients whose tumors had stable or
decreased volume on MRI had 1- and 2-year progression-free
survival rates of 100% and 100%, respectively. For true pro-
gression tumors, the 1- and 1.5-year tumor progression-free
survival rates were 20% and 0%, respectively. The first 2-
year local tumor control rate of pseudoprogression in pa-
tients who had pseudoprogression features on MRI was similar
to those who had a stable or decreased tumor size ( p ¼ 0.364),e) over time of the total 19 tumors after GKRS.
Fig. 2. Bar chart of enhancing pattern and volume changes after gamma knife radiosurgery in the 19 tumors.
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decreasing tumor on MRI exhibited superior local tumor
control to that of patients who had true progression
( p ¼ 0.006) (Fig. 4).
4. Discussion
Ependymal tumors range in WHO grade classification from
I to III,3 and the clinical outcomes vary.4,5 Relapsed ependy-
moma in children yields a poor prognosis, with a previously
reported overall survival rate of 29% at 2 years.6 Thus far,
there remains a lack of novel targeted therapies and adequate
systemic chemotherapy for a cure. Moreover, reoperation and
re-irradiation are often limited and/or associated with
increased difficulties caused by prior treatment. Since the late
1980s, stereotactic radiosurgery has been used and reported to
be an effective alternative to repeated surgical resection or
repeated external beam whole-brain RT in cases of relapsed
disease,7,8 and has been proven to provide effective local
control and may improve survival rates for patients with
limited recurrent disease in recent studies.9e11 In the current
study, the 1-year local control rate was 89%, and the 2-year
overall-survival rate was 81%.
The treatment efficacy of GKRS can be monitored and
evaluated only by neuroimaging. In contrast to conventional
radiotherapy, GKRS is a highly precise and focused form of
irradiation. The focused irradiation results in primarily local
radiation-induced changes. In post-GKRS vestibular schwan-
nomas, a transient increase in size followed by stability or
regression has been increasingly recognized as treatment ef-
fects rather than treatment failures in the first post-GKRS24 months. Pseudoprogression was recently adopted to
describe the transient tumor volume increases of post-GKRS
vestibular schwannomas.12 Initially, the term pseudoprog-
ression was applied to describe glioblastomas that developed
transient tumor progressive deterioration on MRI scans after
postconcomitant chemoradiation therapy with
temozolomide.13e16 The pathophysiological changes of pseu-
doprogression involved in post-GKRS schwannomas might be
different from that of glioblastomas, although neither of the
mechanisms of pseudoprogression has yet to be been fully
elucidated. In glioblastoma, such mechanisms are believed to
be due to a higher chemoradiation-induced degree of (desired)
tumor-cell and endothelial-cell killing with an associated in-
flammatory reaction and abnormal vessel permeability in the
tumor area.13 In contrast, the biological effects of radiosurgery
on vestibular schwannoma cells are believed to be a combi-
nation of acute inflammation and vascular occlusion or
apoptosis.17,18 Why this occurs mainly in schwannomas re-
mains unclear. In the current series, we used the term of
pseudoprogression to describe post-GKRS transient tumor
volume enlargement of ependymomas, although the involved
mechanism might be neither the same as glioblastomas nor
schwannomas. Using sequential volumetric assessment, we
demonstrated that a significant portion of post-GKRS epen-
dymomas presented pseudoprogression within the first post-
GKRS 12 months (58% in all 12 tumors showing initial
enlargement or 37% of all 19 treated tumors). In contrast to
post-GKRS vestibular schwannomas, of which the transient
tumor enlargement mostly last longer than 1 year, all pseu-
doprogression of post-GKRS recurrent anaplastic ependymo-
mas regress within 6 months. In the future, if tumor
Fig. 3. Postcontrast T1-weighted images of a 6-year-old boy on the day of gamma knife radiosurgery and at 6 months, 9 months, and 15 months after gamma knife
radiosurgery. (A) On the date of radiosurgery, there was a small enhancing recurrent tumor in the left frontal near frontal horn (arrow). (B) Six months after
radiosurgery, there was an increasing enhancing area with a central loss-enhancement portion of the treated tumor (arrow). (C) Nine months after radiosurgery, the
enhancing area shrunk without additional treatment (arrow). (D) Fifteen months after radiosurgery, the enhancing lesion further decreased and was not easily
observed in magnetic resonance imaging (arrow).
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6 months, closer imaging follow-up or another adjuvant
treatment might be considered as timely management avenues.
In the current series, the lesions of pseudoprogression not
only showed marginal or irregular ring enhancement with
fuzzy margins similar to the post radiation changes, but also
showed persistent enhancement or new enhancement,
mimicking true progression. The pathological examination of
one pseudoprogression case showed radiation-induced
vascular changes, from which we might infer that radiation-
induced vascular changes is one of the microscopic mecha-
nisms in pseudoprogression. Furthermore, all the cases except
one (a grade II ependymoma) in the current series received
pre-GKRS conventional radiation therapy. The accumulated
irradiation dose, instead of concomitant temozolomide or
chemotherapy, might have been a factor triggering the pseu-
doprogression in the current study. Diffusion weighted imag-
ing was also helpful in differentiating pseudoprogression fromtrue progression. Higher mean post-GKRS ADC values of
enhancing lesions and higher post-GKRS to pre-GKRS ADC
ratios in pseudoprogression than true progression probably
reflects the lower cellularity and/or increased vasogenic edema
caused by radiation-induced vascular changes in
pseudoprogression.
Although achieving tumor regression manifested by neu-
roimaging is the treatment goal, tumor enlargement does not
always indicate treatment failure. In our study, the local tumor
control rate in the first 2 years in patients who had pseudo-
progression was similar to those who had a stable or
decreased tumor size; both groups had better tumor control
rate than those with true progression. In patients with initial
tumor enlargement observed on MRI within the first post-
GKRS 12 months, the management of choice might be
wait-and-see with a closer imaging follow-up prior to true
progression is suggested by continuous and progressive
enlargement.
Table 1
Predictors of pseudoprogression and true progression.
Variable Pseudoprogression True progression p
Age (y) 17 14 0.708
Prior RT dose (cGy) 5320 4754 0.572
Time interval between
RT and GKRS (mo)
57.3 60.9 0.785
Mean GKRS dose (Gy) 20.9 16.7 0.122









Present 3 3 0.92
Absent 4 2
ADC values when enlarged
(103 mm2/s), mean ± SD




1.15 ± 0.11 0.92 ± 0.02 0.005*
Follow up after 6 mo
Enlargement 1 5 0.03*
Decrease in size 6 0
* Statistically significant ( p < 0.05).
ADC ¼ apparent diffusion coefficient; GKRS ¼ gamma knife radiosurgery;
MRI ¼ magnetic resonance imaging; RT ¼ radiation therapy; SD ¼ standard
deviation.
Fig. 4. KaplaneMeier curve of local tumor control. There were no significant diffe
pseudoprogression and those who had a stable or decreased tumor size ( p ¼ 0.364
( p ¼ 0.006).
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tions. First, the treatment modalities and chemotherapy
regimen were heterogeneous. Second, we did not incorporate
advanced MRI techniques, such as MRI spectroscopy and
MRI perfusion, into the studying imaging protocol. Third,
only two patients had surgical and pathological confirmation
of their post-GKRS recurrent tumors. Thus, a comprehensive
pathophysiological explanation of the tumor response to
GKRS is not achievable.
In conclusion, dynamic tumor volume changes in recurrent
ependymomas or anaplastic ependymomas are observed in
serial of post-GKRS MRI follow-up. Pseudoprogression, with
transient initial tumor enlargement, mostly regresses within
6 months, and occurs in 58% of tumors with initial post-GKRS
tumor enlargement. Low-grade ependymoma (WHO grade II)
might require more time to regress. ADC values are simple
and readily available techniques that can help to differentiate
pseudoprogression from true progression after GKRS. Serial
follow-up MRI is also beneficial in differentiation by post-
GKRS tumor enlargement resolved in 6 months indicating
pseudoprogression.
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